Fact-checked by Grok 2 weeks ago

Transport maximum

The transport maximum, denoted as Tm, is the maximum rate at which a substance can be actively reabsorbed or secreted across the epithelial cells of the renal tubules by carrier-mediated transport mechanisms before the system becomes saturated. This concept is central to , as it limits the kidney's ability to handle filtered loads of essential nutrients, ions, and waste products, ensuring while preventing excessive loss in . In practice, Tm varies by substance and is determined experimentally by progressively increasing concentrations and measuring urinary until plateaus. A classic example is glucose in the proximal convoluted tubule via sodium-glucose (SGLTs), where the TmG averages 375 mg/min in healthy adult males and 300 mg/min in females. When the filtered load exceeds TmG, glucosuria occurs, typically beginning at a glucose concentration of approximately 180–200 mg/dL (10 mmol/L). However, due to splay—a physiological phenomenon arising from heterogeneity in transport capacities and variations in carrier affinity—the onset of is gradual rather than abrupt, with full only reached at higher levels around 350 mg/dL. This splay ensures that small amounts of glucose may appear in before the theoretical Tm is exceeded, optimizing renal efficiency. Tm also applies to other substances, such as (with a TmP reached at serum levels of about 6 mg/dL) and para-aminohippuric acid (PAH, used to measure renal , with Tm around 80 mg/min), highlighting the kidney's selective limits. Disruptions in Tm, as seen in conditions like diabetes mellitus where it may increase by up to 20%, or renal tubular disorders, can lead to clinical manifestations such as or imbalances. Understanding Tm is crucial for therapies like SGLT2 inhibitors, which exploit this to promote glucose excretion in management.

Definition and Principles

Definition

The transport maximum (Tm or Tmax) refers to the maximum rate at which a substance can be actively transported across a via carrier-mediated mechanisms, particularly in the renal tubules, beyond which the transport system becomes saturated and excess substance spills into the . This saturation occurs when all available carrier proteins are fully occupied, limiting further transport despite increasing filtered loads. Tm can be distinguished as reabsorptive for substances like glucose, where it represents the upper limit of reuptake from the tubular filtrate back into the , or secretory for substances like para-aminohippuric acid (PAH), where it denotes the peak rate of addition from the blood into the filtrate. A related concept is the , defined as the plasma concentration of a substance at which it first appears in the urine, occurring when the filtered load exceeds the Tm. In healthy individuals, Tm remains a constant value, determined by the total capacity of proteins in the tubules. For example, the Tm for glucose reabsorption is approximately 375 mg/min in adult human males and 300 mg/min in females.

Underlying Mechanisms

The transport maximum (Tm) in renal physiology stems from carrier-mediated active transport systems embedded in the epithelial membranes of the renal tubules, which enable the selective reabsorption of solutes from the glomerular filtrate. These systems typically involve specific transmembrane proteins that bind substrates and translocate them across the cell membrane, often coupled to ion gradients for energy. A prominent example is the sodium-glucose cotransporter (SGLT) family in the proximal convoluted tubule, where SGLT2 predominates in the early segment (S1/S2) and SGLT1 in the later segment (S3), facilitating glucose uptake alongside sodium ions using the electrochemical gradient established by the basolateral Na+/K+-ATPase pump. This secondary active transport mechanism ensures efficient recovery of filtered glucose under normal conditions, preventing its loss in urine. The core of Tm is the saturation phenomenon, where the rate reaches a plateau once all sites are occupied by the , rendering further increases in concentration ineffective for enhancing . This limitation arises because carriers operate with finite numbers of active sites, analogous to , leading to a maximum flux even as availability rises. Consequently, excess spills into the tubular lumen and is excreted, as seen with glucose when plasma levels exceed the . Several factors modulate Tm, including the density of carrier molecules per unit membrane area, which sets the upper limit of transport capacity, and the carrier's affinity for the substrate, expressed as the Michaelis constant ()—the substrate concentration yielding half-maximal transport rate. Lower Km values indicate higher affinity, allowing efficient transport at lower concentrations. Tubular heterogeneity further influences Tm dynamics, causing "splay" in curves: variations in carrier expression, nephron filtration rates, and local tubular flow among nephrons result in a gradual rather than abrupt onset of saturation, with some nephrons reaching capacity before others. In contrast to passive diffusion, which lacks and varies proportionally with concentration gradients via paracellular or simple membrane permeation, Tm exclusively characterizes saturable carrier-dependent processes, such as primary or secondary and . This concept emerged in the mid-20th century from experimental studies on renal glucose handling, pioneered by James A. in and 1940s, who quantified in canine models and drew parallels to Michaelis-Menten to explain limits.

Determination and Measurement

Experimental Methods

Experimental methods for determining the transport maximum (Tm) in primarily rely on clearance techniques and controlled infusion protocols to assess the saturation of tubular or . These approaches involve measuring the filtered load of a substance—calculated as the product of (GFR) and concentration—and comparing it to the rate in . By elevating concentrations of the test substance, researchers identify the point at which saturates, leading to increased urinary . Renal clearance techniques form the foundation of Tm measurement, utilizing substances like or to estimate GFR alongside the test solute, such as glucose or para-aminohippurate (PAH) for studies. and samples are collected over timed periods to compute clearance rates, with complete emptying ensured via catheterization to avoid underestimation of . The technique distinguishes from handling by confirming that the substance is freely filtered at the and not significantly protein-bound, allowing accurate assessment of net or . Historical validation of these methods occurred in models, where simultaneous and glucose clearances revealed consistent maxima. Infusion studies enable precise of levels to probe Tm. In these protocols, animals or subjects receive continuous intravenous of the test substance, often combined with GFR markers like , to achieve steady-state concentrations. levels are incrementally raised while monitoring urine output and composition, generating titration curves that plot filtered load against rate. For glucose, infusions typically start below the and increase until saturation, with steady-state conditions maintained for 30-60 minutes per level to ensure equilibration. This method, pioneered in the 1930s-1940s, demonstrated reproducible Tm values in unanesthetized over multiple sessions. The maximum is calculated at the point as Tm = filtered load - rate, where filtered load is GFR multiplied by concentration, and rate is times urinary concentration. This requires substances that are completely filtered and not metabolized or secreted by tubules, with measurements taken under steady-state conditions to minimize variability. In practice, multiple clearance periods at high levels are averaged to define the plateau. Animal models have been instrumental in validating these techniques, with serving as a primary species due to their physiological similarities to humans and ease of handling. Classic studies reported a glucose Tm of approximately 100 mg/min in weighing 10-15 kg, achieved through repeated infusions without to enhance . In , analogous experiments yielded a lower Tm of about 50 mg/min for glucose, reflecting smaller body size and GFR, and highlighting species-specific differences in capacity. These models underscored the stability of Tm measurements across sessions, supporting their use in physiological . Key considerations in these experiments include accounting for variations in GFR, which can alter filtered load and confound Tm estimates; thus, GFR is continuously monitored and stabilized. Complete collection is critical, often verified by recovery of infused markers exceeding 90%. Additionally, the observed "splay"—a gradual rather than abrupt increase in near the —arises from heterogeneity among nephrons in transport capacity and GFR, necessitating careful to extrapolate true Tm. These factors ensure reliable data but require rigorous controls to avoid artifacts from hydration status or . Contemporary methods complement classical approaches, incorporating micropuncture techniques for direct sampling in animal models and non-invasive imaging, such as (), to assess Tm in humans ethically. These advancements, often integrated with computational simulations, allow for more precise and personalized Tm estimates as of 2025.

Mathematical Modeling

The mathematical modeling of maximum (Tm) in draws directly from , treating carrier-mediated as a saturable where transporters bind substrates with limited . This analogy arises because renal carriers, such as sodium-glucose , function similarly to enzymes by reversibly substrates and undergoing conformational changes to facilitate translocation across the , with the overall rate limited by the number of available carriers and their turnover rate. The derivation of the model begins with the assumption of steady-state : the rate of substrate to free carriers equals the rate of release, leading to a relationship between rate and substrate concentration. Specifically, V_max represents the product of total carrier concentration and the maximum turnover rate (k_cat), while K_m reflects the affinity of the carrier for the , incorporating dissociation constants for loaded and unloaded states. The core equation describing the transport rate J is the Michaelis-Menten equation: J = \frac{V_{\max} \cdot [S]}{K_m + [S]} Here, V_max corresponds to the Tm, the maximum rate at which the substance can be across the tubular epithelium; [S] is the concentration (typically luminal or filtered load); and K_m is the concentration yielding half of V_max, indicating the transporter's . At low [S] (much less than K_m), transport is linear and proportional to [S], approximating complete ; as [S] approaches or exceeds K_m, occurs, and J plateaus at V_max. For glucose reabsorption, primarily mediated by SGLT2 in the early , K_m is low (approximately 5-10 mM), ensuring near-complete reabsorption under normal concentrations below the . The , the plasma concentration at which the substance first appears in urine, relates to Tm via the approximation threshold ≈ Tm / , where GFR is the . This marks the point where the filtered load (GFR × plasma concentration) equals Tm, initiating overflow . In practice, curves deviate from ideal Michaelis-Menten behavior due to "splay," a non-linear in the curve where begins before reaching the theoretical Tm / GFR. Splay arises from heterogeneity in Tm across , modeled as variable carrier distribution or affinity among proximal tubules, causing some nephrons to saturate earlier than others and resulting in gradual rather than abrupt . This variability can be quantified by fitting composite models with distributed K_m or V_max parameters to experimental data, highlighting the impact of nephron diversity on overall .

Physiological Role

In Reabsorption

The transport maximum (Tm) plays a central role in the of essential substances from the glomerular filtrate in the , primarily occurring in the proximal convoluted tubule where approximately 90% of reabsorption takes place via carrier-mediated mechanisms limited by Tm. These carriers handle nutrients such as , , and , ensuring their efficient recovery to maintain while preventing wasteful . In the case of glucose, which is freely filtered at the , is nearly complete under normal conditions when plasma glucose levels are below the of approximately 10 mM (180 mg/dL). The Tm for glucose in the is about 350–375 mg/min, beyond which the filtered load exceeds carrier capacity, resulting in as excess glucose spills into the urine. This saturation mechanism conserves glucose as a vital energy source while allowing the to excrete surplus during . Bicarbonate reabsorption, also predominantly in the proximal tubule, relies on a Tm of approximately 3–4 mEq/min (equivalently, a tubular threshold of ~25 mEq/L), which is essential for regulating acid-base balance by reclaiming most of the filtered load and preventing metabolic acidosis. Similarly, phosphate reabsorption follows Tm-limited kinetics in the proximal tubule, with the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) typically ranging from 0.8 to 1.35 mmol/L, though this value varies with dietary phosphate intake and parathyroid hormone levels. The efficiency of Tm-dependent reabsorption ensures the conservation of vital solutes, where the amount reabsorbed equals the filtered load (fractional reabsorption = 1) when below Tm but equals Tm (fractional reabsorption = Tm / filtered load) upon saturation, reflecting carrier availability. While Tm is generally fixed, it can adapt modestly to chronic high filtered loads, such as during where glucose reabsorptive capacity increases to accommodate elevated glomerular filtration rates without significant .

In Secretion

In renal tubular secretion, the transport maximum (Tm) represents the maximum rate at which substances can be actively transported from the into the tubular lumen, primarily occurring in the . This process involves basolateral uptake across the blood-facing membrane followed by apical secretion into the filtrate, mediated by specific carrier proteins such as organic anion transporters (OATs). For instance, para-aminohippurate (PAH) is taken up at the basolateral membrane via OAT1 and OAT3, and then secreted apically through multidrug resistance-associated protein 4 (MRP4). Similarly, undergoes secretion via organic cation transporters (OCTs) like OCT2 on the basolateral side and apical efflux transporters. A key example of Tm in is PAH, where the transport maximum in humans is approximately 80 mg/min, reflecting the saturation of carrier-mediated transport when levels exceed the threshold. This Tm value is utilized in to understand the limits of capacity, particularly in the context of estimating effective flow (ERPF), as PAH at subsaturating concentrations approximates ERPF due to near-complete . When is saturated, excess PAH appears in the beyond the filtered load, highlighting the finite number of transporters available. Tm plays a crucial role in maintaining by facilitating the elimination of organic acids and bases, such as , preventing their systemic accumulation. For , secretion occurs primarily in the via OATs and other transporters, with the process limited by a transport maximum that ensures regulated rates, typically contributing to a net fractional excretion of about 10%. This secretory capacity helps clear and xenobiotics, including drugs, though it caps the rate of elimination to avoid overload on the transport systems. Certain substances exhibit bidirectional transport, where both reabsorptive and secretory Tm mechanisms operate, resulting in net handling determined by the balance of these fluxes. exemplifies this, with secretory Tm contributing to alongside predominant , modulated by plasma levels and transporter activity. In general, secretory Tm for many substances tends to be lower than reabsorptive Tm, attributable to a relatively smaller complement of secretory carriers compared to those dedicated to reclamation.

Clinical Implications

Pathological Conditions

In diabetes mellitus, frequently exceeds the renal transport maximum (Tm) for glucose reabsorption in the , resulting in when the filtered glucose load surpasses the capacity of sodium-glucose SGLT2 and SGLT1. This induces osmotic diuresis, promoting , dehydration, and electrolyte imbalances that complicate glycemic control. In chronic cases, progressive loss from reduces the overall Tm and lowers the plasma glucose threshold for , exacerbating urinary glucose loss even at moderately elevated blood levels. Fanconi syndrome represents a generalized proximal tubule dysfunction that impairs the Tm for reabsorption of glucose, , , and other solutes, leading to their excessive urinary wasting. This defect disrupts the normal sodium-coupled transport mechanisms in the segments, causing , aminoaciduria, and glucosuria despite normoglycemia. The resulting depletion often manifests as rickets-like bone deformities, , and growth impairment in affected individuals, particularly children. Uric acid disorders, including , frequently involve alterations in the tubular Tm for urate handling, where reduced secretory Tm or enhanced reabsorptive Tm limits net urate excretion and promotes . In the , impaired secretion via transporters like URAT1 and family members, combined with increased postsecretory , accounts for underexcretion in up to 90% of cases. indirectly modulates this by inhibiting to decrease urate production, thereby reducing the filtered load and easing the burden on altered transport capacities. Chronic renal failure diminishes the Tm for various solutes due to reduced nephron mass, which proportionally lowers the kidney's overall reabsorptive and secretory capacities. This nephron loss impairs toxin clearance, contributing to uremia as the remaining nephrons undergo compensatory hypertrophy but fail to fully offset the global transport deficit. Inherited defects in glucose transport, such as mutations in the SLC5A2 gene encoding SGLT2, underlie familial renal glucosuria, where the Tm for renal glucose reabsorption is selectively reduced, causing persistent glucosuria without hyperglycemia or other metabolic disturbances. These loss-of-function variants disrupt the high-capacity SGLT2-mediated reabsorption in the early proximal tubule, leading to urinary glucose losses ranging from mild to severe, but typically without long-term renal or systemic complications.

Diagnostic Uses

In clinical diagnostics, the renal threshold for glucose reabsorption, which approximates the transport maximum (Tm), is indirectly evaluated during oral glucose tolerance tests by observing the onset of . Normally, occurs when plasma glucose exceeds approximately 180 mg/dL; a lower suggests impaired tubular reabsorption capacity, which can indicate renal tubular dysfunction in the context of or other conditions. This assessment helps differentiate hyperglycemia-induced in from isolated , where Tm is reduced despite normal blood glucose levels. Para-aminohippuric acid (PAH) clearance at low plasma concentrations (1–2 mg/dL) serves as a key diagnostic method for assessing effective (ERPF), calculated as ERPF = (U_PAH × V) / P_PAH, where U_PAH is urine PAH concentration, V is , and P_PAH is PAH concentration; this approximates 90% of true renal flow due to near-complete . At saturating concentrations (40–60 mg/dL), the maximum secretion rate (TmPAH) is determined as TmPAH = (U_PAH × V) - (P_PAH × GFR × 0.83), where GFR is and 0.83 corrects for protein binding; this quantifies secretory capacity and detects impairments, such as in . Phosphate reabsorption tests measure the Tm for phosphate per glomerular filtration rate (TmP/GFR), providing insights into parathyroid function and associated bone diseases. This ratio is derived from fasting serum and urine phosphate and creatinine levels using the formula TmP/GFR = serum phosphate − (urine phosphate × serum creatinine / urine creatinine); normal adult values range from 2.5 to 4.5 mg/dL. Reduced TmP/GFR indicates phosphaturic effects of elevated parathyroid hormone, as seen in primary hyperparathyroidism, while elevated values may signal hypoparathyroidism or tumoral calcinosis. Aminoaciduria screening via chromatographic analysis of urine amino acid profiles identifies reduced Tm for specific substrates, aiding of inherited proximal tubular disorders. In , for instance, mutations in the SLC3A1 or SLC7A9 genes impair the dibasic transporter, leading to excessive urinary excretion of cystine, , , and , with cystine concentrations often exceeding 250 mg/day confirming the . This non-invasive test distinguishes from other stone-forming conditions and guides preventive management. Modern diagnostic applications extend Tm assessment through advanced imaging and therapeutic monitoring. Post-2020 studies have explored () with SGLT-targeted tracers, such as 18F-labeled agents, to visualize and quantify renal glucose transport dynamics , offering potential for non-invasive Tm evaluation in and . Additionally, sodium-glucose 2 (SGLT2) inhibitors, like empagliflozin, are used in treatment to lower the effective glucose Tm by 20-50%, promoting and improving glycemic control; serial Tm measurements via clearance studies monitor therapeutic efficacy and renal adaptation.

References

  1. [1]
    None
    ### Summary of Tubular Transport Maximum (Tm), Renal Threshold, and Splay
  2. [2]
    [PDF] (Renal Physiology.kp)
    characterized by a transport maximum, Tm. A good example is that of glucose. This molecule is actively reabsorbed, up to a maximum amount per unit time.
  3. [3]
    Renal glucose handling in diabetes and sodium glucose ... - NIH
    At this threshold, the system becomes saturated and the maximal resabsorption rate, the glucose transport maximum (TmG), is reached. ... splayed threshold of ...<|control11|><|separator|>
  4. [4]
    Renal phosphate handling: Physiology - PMC - NIH
    However, a maximum rate of transport (Tm) for phosphorus reabsorption is obtained usually at serum phosphorus concentrations of 6 mg/dL. There is a direct ...
  5. [5]
    [PDF] The Urinary System: Part A
    Oct 20, 2014 · Transport Maximum. • Transcellular transport systems specific and limited. – Transport maximum (Tm) for ~ every reabsorbed substance; reflects ...Missing: definition | Show results with:definition
  6. [6]
    [PDF] AMINOHIPPURATE SODIUM* "PAH" - accessdata.fda.gov
    PAH is also used to measure the functional capacity of the renal tubular secretory mechanism or transport maximum (TmPAH). This is accomplished by elevating ...
  7. [7]
    [PDF] THE KIDNEY AND THE CONCEPT OF CLEARANCE * - Holy Cross
    1. The point where this first starts to happen is called the RENAL THRESHOLD and the concentration where Vmax is reached is called the TUBULAR MAXIMUM or Tm.
  8. [8]
    The Urinary System - OERTX
    In men, the maximum amount of glucose that can be recovered is about 375 mg/min, whereas in women, it is about 300 mg/min. This recovery rate translates to an ...
  9. [9]
    Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
    Aug 22, 2018 · Three membrane proteins are responsible for glucose reabsorption from the glomerular filtrate in the proximal tubule: sodium−glucose cotransporters SGLT1 and ...
  10. [10]
    Physiology, Renal - StatPearls - NCBI Bookshelf - NIH
    Jul 24, 2023 · The distensibility of the bladder allows it to hold a maximum capacity of up to 1000ml, though normal functional capacity is 300 to 400mL.[13] ...
  11. [11]
    Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and ...
    Nov 19, 2015 · In the 1930s, Shannon and Fisher elucidated the renal glucose reabsorption kinetics in dogs (10). Their work showed that 1) there is a maximum ...
  12. [12]
    Transport Maximum - an overview | ScienceDirect Topics
    This characteristic is called splay and is thought to result from nephron heterogeneity. Some nephrons excrete glucose before the average Tmax is reached ...
  13. [13]
    The development of clearance methods for measurement of ...
    Aug 23, 2004 · With the measurement of GFR in hand, glucose transport could be quantified, and Shannon did ... transport maximum (Tm) for glucose. In subsequent ...
  14. [14]
    The development of clearance methods for measurement of ...
    They explicitly raised the potential value of measuring tubular transport maxima in assessing kidney function.Missing: determining | Show results with:determining
  15. [15]
    Mechanistic Models Describing Active Renal Reabsorption and ...
    The Michaelis–Menten parameters for renal transport can be estimated based on in vitro or in vivo data. Both Km and Vmax parameters may be estimated from in ...
  16. [16]
  17. [17]
  18. [18]
    Glucose transporters in the kidney in health and disease - PMC - NIH
    The maximum renal transport capacity (Tmax) for glucose averages around 300 and 350 mg/min or 430 and 500 g/day in female and male healthy individuals, ...
  19. [19]
    THE TUBULAR MAXIMA PAGE
    Jan 5, 2009 · This threshold rate of reabsorption, or "tubular maximum for glucose" is denoted as TM G. The kidneys can reabsorb glucose no faster than 300 mg/min!Missing: definition | Show results with:definition
  20. [20]
    On the influence of extracellular fluid volume expansion on ... - NIH
    Bicarbonate reabsorption is classically regarded as a rate-limited process characterized by saturation kinetics. The tubular maximum (Tm), however, varies with ...
  21. [21]
    Roles of organic anion transporters (OATs) in renal proximal tubules ...
    The prototypical substrate for renal organic anion transport systems, para-aminohippurate (PAH), is transported across basolateral membranes of proximal tubular ...
  22. [22]
    Dynamics of Organic Anion Transporter-Mediated Tubular Secretion ...
    Mar 18, 2019 · In humans, PAH can be used to measure the effective renal plasma flow (ERPF) and the maximum tubular secretory capacity (TmPAH); the latter is ...
  23. [23]
    Uric acid transport, transporters, and their pharmacological targeting
    Apr 24, 2023 · Normal fractional excretion of UA (FEUA) is approximately 10% (range 7%–12%) and is usually slightly higher in females and children.4.2. 1 Urat1 · 4.3 Glut9 · 5 Inhibitors Of Ua Transport
  24. [24]
  25. [25]
    Glucose Metabolism in the Kidney: Neurohormonal Activation and ...
    Nov 14, 2020 · In patients with T2DM, the renal threshold of glycosuria, as well as TmG, is higher. The TmG can correlate with the increase in HbA1c, and ...
  26. [26]
    Physiology, Glycosuria - StatPearls - NCBI Bookshelf
    Mar 13, 2023 · In normal individuals, glucosuria can be up to 0.25 mg/ml. More than 0.25 mg/ml in random fresh urine is considered increased glucosuria and can ...Introduction · Organ Systems Involved · Mechanism · Pathophysiology
  27. [27]
    Learning From Glycosuria - American Diabetes Association
    Feb 21, 2011 · With a 50% reduction in Tm G, glycosuria would appear at a plasma glucose level of 90 mg/dL and rise to 80 g per day at a plasma glucose of 150 mg/dL.
  28. [28]
    Fanconi Syndrome - StatPearls - NCBI Bookshelf
    Jun 24, 2025 · Fanconi syndrome is a rare disorder that affects the kidney's proximal tubules, leading to impaired reabsorption of substances.Missing: maximum | Show results with:maximum
  29. [29]
    Fanconi Syndrome and Other Proximal Tubule Disorders
    Jun 4, 2016 · Fanconi syndrome now refers to a global dysfunction of the proximal tubule leading to excessive urinary excretion of amino acids, glucose, phosphate, ...Fanconi Syndrome · Inherited Causes Of Fanconi... · Cystinosis
  30. [30]
    Fanconi Syndrome - U.S. Pharmacist
    Jun 20, 2011 · Fanconi syndrome is a disease that is associated with dysfunction of the proximal tubule of the kidney.
  31. [31]
    Renal handling of uric acid in gout: Impaired tubular transport of ...
    These data suggest an impaired tubular secretion of urate in most patients with gout that is not normalized by decreasing serum urate levels.
  32. [32]
    Hyperuricemia - StatPearls - NCBI Bookshelf - NIH
    Oct 14, 2023 · Hyperuricemia is defined as an elevated serum uric acid level, usually greater than 6 mg/dL in women and 7 mg/dL in men.
  33. [33]
    Hyperuricemia and its related diseases: mechanisms and advances ...
    Aug 28, 2024 · The majority of uric acid is filtered in its free form, with approximately 90% of the filtered UA being reabsorbed. Hyperuricemia can be ...
  34. [34]
    Remnant nephron physiology and the progression of chronic kidney ...
    In chronic kidney disease, ongoing failure of individual nephrons leads to the progressive loss of renal function.Missing: maximum | Show results with:maximum
  35. [35]
    Physiology and Pathophysiology of Compensatory Adaptations of a ...
    Congenital anomalies of the kidney and urinary tract (CAKUT) represent the primary cause of chronic kidney disease (CKD) in the pediatric population, accounting ...
  36. [36]
    Genetic and clinical characterization of familial renal glucosuria
    Oct 17, 2023 · Familial renal glucosuria (FRG) is a hereditary disorder caused by variants in SLC5A2 encoding sodium-glucose cotransporter 2 (SGLT2).INTRODUCTION · MATERIALS AND METHODS · RESULTS · DISCUSSION
  37. [37]
    Elevation of the renal threshold for glucose is associated with insulin ...
    It is generally accepted that when blood glucose concentrations exceed ~180 mg/dL, urinary glucose excretion occurs, and this blood glucose concentration is ...
  38. [38]
    Glucosuria Is Not Always Due to Diabetes - PMC - NIH
    Familial renal glucosuria is an uncommon, rarely documented condition wherein the absence of other renal or endocrine conditions and with a normal serum glucose ...
  39. [39]
    Aminohippuric acid: Uses, Interactions, Mechanism of Action
    Jun 13, 2005 · Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. ... transport maximum (TmPAH) ...Interactions · Spectra · Transporters
  40. [40]
    The basics of phosphate metabolism - Oxford Academic
    The range of normal TmP:GFR values differs with age and sex. In female adults it ranges between 0.8 and 1.44 mmol/l (2.0–3.6 mg/dl), while in males it ranges ...
  41. [41]
    Phosphate Metabolism and Pathophysiology in Parathyroid ... - NIH
    Nov 30, 2021 · It is unusual to find patients with primary hyperparathyroidism and serum phosphate values above 3.5 mg/dL in the absence of significant renal ...Missing: Tm/ | Show results with:Tm/
  42. [42]
    Cystinuria: An Overview of Diagnosis and Medical Management - PMC
    Cystinuria is caused by mutations in genes encoding proximal tubule dibasic amino acid transporter which facilitates reabsorption of cysteine, ornithine, lysine ...
  43. [43]
    Cystinuria: clinical practice recommendation - Kidney International
    Sep 9, 2020 · The diagnosis of cystinuria is confirmed by the measurement of increased levels of cystine and dibasic amino acids (ornithine, lysine, and ...
  44. [44]
    Recent Advances and Future Trends of[18F]-Labeled PET Agents ...
    Oct 18, 2025 · Novel functional renal PET imaging with 18F-FDS in human subjects ... Recent advancements have leveraged SGLT-targeted PET imaging to examine ...
  45. [45]
    Empagliflozin and Kinetics of Renal Glucose Transport in Healthy ...
    In summary, sodium-glucose transporter-2 inhibition with empagliflozin reduces both TmG and threshold for glucose spillage in the urine in patients with T2DM ...